GTS Securities’s CRISPR Therapeutics CRSP Stock Holding History

GTS Securities’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$370K	Buy	+7,787	New	+$411K	0.01%	961
2025 Q4	–	Sell	-20,696	Closed	-$1.34M	–	1455
2025 Q3	$1.34M	Buy	+20,696	New	+$1.19M	0.05%	308
2024 Q4	–	Sell	-51,607	Closed	-$2.42M	–	1872
2024 Q3	$2.42M	Buy	51,607 +10,396	+25%	+$527K	0.01%	1435
2024 Q2	$2.23M	Buy	41,211 +21,934	+114%	+$1.27M	﹤0.01%	1417
2024 Q1	$1.31M	Sell	19,277 -50,095	-72%	-$3.59M	﹤0.01%	1787
2023 Q4	$4.34M	Buy	69,372 +27,866	+67%	+$1.54M	0.01%	1096
2023 Q3	$1.88M	Buy	41,506 +13,908	+50%	+$718K	﹤0.01%	1560
2023 Q2	$1.55M	Buy	+27,598	New	+$1.57M	0.05%	317

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GTS Securities's CRSP Position: Q1 2026 in Review

GTS Securities opened a new position in CRISPR Therapeutics (CRSP) in Q1 2026: 7,787 shares worth $370K. The stake represents 0.01% of the portfolio and ranks #961 among its holdings. This is a return to the name: GTS Securities previously reported a position in CRSP as recently as Q3 2025.

GTS Securities first reported a position in CRSP in Q2 2023 and has held it in 8 quarters since. The position peaked at $4.34M in Q4 2023. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

GTS Securities held 7,787 shares of CRISPR Therapeutics worth $370K as of Q1 2026.
CRISPR Therapeutics was a new GTS Securities position in Q1 2026.
CRISPR Therapeutics made up 0.01% of GTS Securities's portfolio in Q1 2026, its #961 holding.
GTS Securities first reported a position in CRISPR Therapeutics in Q2 2023 and has held it in 8 quarters since.
GTS Securities's CRISPR Therapeutics position peaked at $4.34M in Q4 2023.
488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on GTS Securities's 13F filing for Q1 2026, filed 15 May 2026.